Cure8 research brief
Intestinal fibrosis (stricture) is a serious, hard-to-treat complication of IBD/Crohn's disease. This preclinical study tests whether an antifibrotic drug used in lung fibrosis might reduce fibrosis in the gut, which could eventually point to new treatments for fibrostenotic disease.
Researchers studying IBD fibrosis or antifibrotic therapies; clinicians following emerging treatments for fibrostenotic Crohn's disease; patients interested in future drug development for stricturing disease.
This PubMed abstract reports a preclinical (mouse DSS) study comparing the antifibrotic effects of nintedanib to prednisolone and sulfasalazine. Nintedanib produced modest reductions in inflammation markers and collagen deposition versus the conventional drugs but did not normalize cytokine levels or restore colon length to healthy values.
The paper frames these as preliminary results supporting further research into nintedanib for fibrostenotic Crohn's disease.
This is an animal (mouse) study using a DSS-induced intestinal fibrosis model; results are preliminary and do not demonstrate safety or efficacy in humans. Quantitative thresholds for antifibrotic effects in preclinical models are not standardized, and the study reports modest benefits that require further validation in additional preclinical work and clinical trials.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.
This is an early positive interim report of a new oral drug (ALK5 inhibitor) aimed at fibrostenosing Crohn’s disease. Treatments that target intestinal strictures are an important area of research for people with...
This report describes an investigational drug that appears to reach its intestinal target and produced molecular changes in biopsies from people with fibrostenosing Crohn’s — a form that causes scarring and strictures.
